6 +/- A 11.5) completed the EQ-5D post-PCI. The EQ-5D levels were dichotomized
into ‘no problems’ (level 1) versus ‘problems’ (levels 2, 3); the visual analogue scale (VAS) was dichotomized using the 25th percentile (cut-off a parts per thousand currency sign60) indicating poor health status. Patients were followed up for 1-year clinical events (death or non-fatal myocardial infarction (MI)).
There were 53 deaths/MIs at follow-up. The EQ-5D health status dimensions mobility (HR:2.23; 95% CI:1.25-3.97), self-care (HR:3.09; 95% CI:1.54-6.20), and self-reported health status as measured with the EQ-VAS (HR:2.94; 95% CI:1.65-5.25) were independent predictors of death/MI and added to the predictive value of a model comprised of demographic and clinical characteristics. The EQ-5D dimensions usual activities, pain/discomfort, and anxiety/depression were not associated with adverse clinical events in adjusted analysis.
Patient-rated find protocol health status predicted adverse clinical events at 1-year follow-up in PCI patients treated with drug-eluting stenting, with the risk being more than 2-fold independent of disease severity and other demographic and clinical characteristics. It may be timely to adopt standard assessment of health status
in clinical practice.”
“Background Traditional FT catalysts such as Co and Fe still suffer from carbon-induced deactivation even with alkali promotion. The objective of this study was to examine the effect of Ba addition to carbon-tolerant Mo carbide since it has Pt-like characteristics and is cheaper than noble metals as an FT catalyst. Results The presence of Ba increased RSL3 order the Mo carbide production rate and reduced the activation energy for its formation. The promoted catalyst exhibited higher specific basic site strength and CO2 uptake for strong basic site than that of the undoped catalyst. Both catalysts exhibited optimal reaction rate at a H2 mole fraction of 0.75 while CO consumption rate, total olefin-to-paraffin ratio, methane suppression as well as C5+ selectivity
were improved with Ba addition. The non-standard Anderson-Schulz-Flory (ASF) product distribution Pinometostat clinical trial observed for the Ba-doped catalyst may be due to the appearance of an additional polymerization site on the catalyst surface located in the BaMoO4 phase. Chain growth factor was enhanced by up to 93% from 0.43 to 0.83 with the Ba-doped catalyst. Conclusions Ba promoter increased chain growth probability by about 93%. The deviation of product distribution from standard ASF plots with 2 chain growth factors for the 3wt%Ba-10%MoC1-x/Al2O3 catalyst was probably due to the presence of different active sites for chain initiation. The result is unprecedented and represents excellent opportunity for industrial exploitation of a new and relatively cheap carbon-resistant catalyst.(c) 2012 Society of Chemical Industry”
“Advanced biliary tract carcinomas represent a group of aggressive diseases that still carries a poor prognosis.